Mankind Pharma Limited
Listed as MANKIND: its shares held by funds are on the stock page.
% of scheme: the share of the scheme's net assets, as the fund house states it. Sep 2026: "—" = no Sep 2026 portfolio from that fund house.
| Security | Grade or sector, as printed | Held | Schemes |
|---|---|---|---|
| 7.97% Mankind Pharma Limited (16/11/2027) ** Bond / debenture · INE634S07033 | CRISIL AA+ / CRISIL-AA+ / ICRA AA+ | ₹487 cr | 16 |
Name, and the credit agency grade (or a sector, where the fund house prints one), as the fund houses print them: several spellings, the most common; several grades, all of them, most common first. This site gives no view on credit.
| Month | Held | Schemes | Fund houses holding / covered |
|---|---|---|---|
| Oct 2026 | ₹487 cr | 16 | 8 / 38 |
| Sep 2026 | ₹1,410 cr | 23 | 9 / 38 |
| Aug 2026 | ₹1,202 cr | 19 | 9 / 37 |
| Jul 2026 | ₹1,202 cr | 20 | 10 / 39 |
| Jun 2026 | ₹1,178 cr | 16 | 9 / 38 |
| May 2026 | ₹1,173 cr | 16 | 9 / 39 |
| Apr 2026 | ₹1,207 cr | 16 | 9 / 39 |
| Mar 2026 | ₹1,658 cr | 17 | 9 / 39 |
| Feb 2026 | ₹2,302 cr | 18 | 9 / 42 |
| Jan 2026 | ₹2,450 cr | 19 | 8 / 41 |
| Dec 2025 | ₹2,720 cr | 20 | 8 / 41 |
| Nov 2025 | ₹2,725 cr | 20 | 8 / 40 |
| Oct 2025 | ₹2,648 cr | 18 | 7 / 38 |
| Sep 2025 | ₹3,292 cr | 29 | 9 / 33 |
A month with fewer fund houses covered is not comparable in full with one with more. Bonds, debentures, commercial paper, certificates of deposit, securitised debt and preference shares a company, bank or trust issued, as each fund house lists them in its monthly portfolio. Government securities, REIT/InvIT units and fund units are not included. Credit agency grades are copied as the fund house prints them; this site gives no view on credit. Not investment advice.